Concord Biotech Invests in Celliimune Biotech for Pioneering Cancer Research

Concord Biotech Ltd has invested in Celliimune Biotech Private Limited with an objective to advance pioneering research in DNA engineering for cancer therapeutics and to develop innovative alternatives to conventional chemotherapy. The investment was made on April 02, 2026, for a cash consideration of Rs. 66,00,000, acquiring 100% equity of Celliimune Biotech Private Limited. Celliimune is working on developing technology for specializing in the discovery, development, and commercialization of novel cell and gene therapy solutions.